Can I read Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease on EtoBox?

Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease by V. Tabar & H. Sarva & A. M. Lozano & A. Fasano & S. K. Kalia & K. K. H. Yu & C. Brennan & Y. Ma & S. Peng & D. Eidelberg & M. Tomishima & S. Irion & W. Stemple & N. Abid & A. Lampron & L. Studer & C. Henchcliffe is a book available to read on EtoBox.

What is Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease about?

Nature, doi:10.1038/s41586-025-08845-yParkinson’s disease is a progressive neurodegenerative condition with a considerable Open accesshealth and economic burden1. It is characterized by the loss of midbrain dopaminergic Check for updatesneurons and a diminished response to symptomatic medical or surgical therapy as the disease progresses2. Cell therapy aims to replenish lost dopaminergic neurons and their striatal projections by intrastriatal grafting. Here, we report the results of an open-label phase I clinical trial (NCT04802733) of an investigational cryopreserved, of-the-shelf dopaminergic neuron progenitor cell product (bemdaneprocel) derived from human embryonic stem (hES) cells and grafted bilaterally into the putamen of patients with Parkinson’s disease. Twelve patients were enrolled sequentially in two cohorts—a low-dose (0.9 million cells, n = 5) and a high-dose (2.7 million cells, n = 7) cohort—and all of the participants received one year of immunosuppression. The trial achieved its primary objectives of safety and tolerability one year after transplantation, with no adverse events related to the cell product. At 18 months after grafting, putaminal 18Fluoro-DOPA positr

Author

V. Tabar & H. Sarva & A. M. Lozano & A. Fasano & S. K. Kalia & K. K. H. Yu & C. Brennan & Y. Ma & S. Peng & D. Eidelberg & M. Tomishima & S. Irion & W. Stemple & N. Abid & A. Lampron & L. Studer & C. Henchcliffe

Publisher

x

Published

2025

Language

EN